A randomized trial of interleukin-2 during withdrawal of antiretroviral treatment (Q35014676)

5 August 2017

title

A randomized trial of interleukin-2 during withdrawal of antiretroviral treatment (English)

1 reference

5 August 2017

main subject

anti-retroviral agent

0 references

author name string

Ronald J Bosch

1

1 reference

5 August 2017

Richard B Pollard

2

1 reference

5 August 2017

Alan Landay

3

1 reference

5 August 2017

Evgenia Aga

4

1 reference

5 August 2017

Lawrence Fox

5

1 reference

5 August 2017

Ronald Mitsuyasu

6

1 reference

5 August 2017

AIDS Clinical Trials Group A5132 Team

7

1 reference

5 August 2017

publication date

3 February 2011

1 reference

Journal of Interferon and Cytokine Research

5 August 2017

published in

1 reference

5 August 2017

volume

31

1 reference

5 August 2017

issue

6

1 reference

5 August 2017

page(s)

481-483

1 reference

Continuing or adding IL-2 in patients treated with antiretroviral therapy (ACTG Protocol A5051, a rollover trial of ACTG Protocol A328)

5 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3104401

Interleukin-2 therapy in patients with HIV infection

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3104401

Treatment interruption as a tool to measure changes in immunologic response to HIV-1.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3104401

A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024).

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3104401

Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3104401

Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3104401

Differential effect of interleukin-2 treatment on primary and secondary immunizations in HIV infected individuals

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3104401

Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial).

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3104401

Interruption of Antiretroviral Therapy Initiated during Primary HIV-1 Infection: Impact of a Therapeutic Vaccination Strategy Combined with Interleukin (IL)-2 Compared with IL-2 Alone in the ANRS 095 Randomized Study

25 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21291323

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21291323

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1089/JIR.2010.0119

1 reference

5 August 2017

1 reference

5 August 2017

1 reference